Celon Pharma

CLN.WAPhase 2

Celon Pharma is a publicly traded, integrated pharmaceutical company based in Poland, with a strong focus on research and development. It employs over 160 scientists and leverages revenue from its generic drug portfolio to fund innovative drug discovery programs targeting cancers, neurological diseases, and metabolic disorders. The company's strategic direction includes partnerships, such as the collaboration with Tang Capital to establish Novohale Therapeutics, to advance its pipeline.

Market Cap

$1.1B

Employees

160+ (R&D scientists alone); total likely 300-500

Focus

Generic DrugsSmall Molecules

AI Company Overview

Technology Platform

Integrated R&D and manufacturing capabilities with a large in-house team of PhD scientists focused on discovering new classes of drugs in oncology, neurology, and metabolic diseases.

Pipeline Snapshot

11 drugs in pipeline

Drug	Indication	Stage
CPL500036 - low dose + CPL500036 - high dose + Placebo	Schizophrenia	Phase 2
Esketamine DPI - low dose + Esketamine DPI - medium dose + Esketamine DPI - high...	Bipolar Depression	Phase 2
CPL207280 + Placebo	Type 2 Diabetes	Phase 2
Esketamine DPI - low dose + Esketamine DPI - medium dose + Esketamine DPI - high...	Major Depressive Disorder	Phase 2
CPL500036 - low dose + CPL500036 - high dose + Placebo	Parkinson Disease	Phase 2

Funding History

IPOUndisclosedUndisclosedJun 30, 2017

Opportunities

The primary growth opportunity lies in successfully advancing its innovative pipeline in high-value therapeutic areas (oncology, neurology, metabolic) to create proprietary, globally licensable assets.

Expanding the geographic reach of its generic and innovative products beyond Poland presents another significant avenue for growth.

Strategic partnerships, like the one with Tang Capital, can provide non-dilutive funding and expertise for specific programs.

Risk Factors

Key risks include clinical failure of its R&D pipeline, which is critical for future valuation.

The company also faces pricing and competitive pressures in its generic drug business, which funds its innovation.

Geographic concentration in Poland and dependence on strategic partners for development and commercialization introduce additional execution risks.

Competitive Landscape

Celon Pharma competes with both generic drug manufacturers and innovative biopharma companies. Its differentiation stems from its integrated 'bench-to-market' model in Poland, using stable generic revenue to fund proprietary R&D. This hybrid model allows it to pursue innovation while mitigating the financial volatility typical of early-stage biotechs.

Publications

Patents

Pipeline